Herantis Pharma: Results for the First Half Year January 1 – June 30, 2021
Herantis Pharma Plc Company Release August 26, 2021, at 9:00 a.m. EEST/8:00 a.m. CEST Dr. Craig Cook CEO of Herantis commented: “In 2021, Herantis continued to optimize its assets and shape the company for future success as we transformed into a pure play CNS biotech company. The continued generation of strong data prompted our strategic decision to focus on our CNS assets, CDNF and xCDNF (HER-096). Following more than a decade of extensive R&D for CDNF and xCDNF, we are now reaping the fruits of those efforts.” Herantis Pharma Plc (“Herantis”), focusing on disease modifying